ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy and safety of Shenfu injection for the treatment of post-acute myocardial infarction heart failure: A systematic review and meta-analysis

Wu, Yanhua; Li, Shuang; Li, Zunjiang; Mo, Zhaofan; Luo, Ziqing; Li, Dongli; Wang, Dawei; Zhu, Wei*; Ding, Banghan*广东省人民医院; 广州中医药大学; 1
Frontiers in Pharmacology2022-11-24DOI: 10.3389/fphar.2022.1027131
1被引10阅读
引用收藏
分享

摘要

Objective: This systematic review and meta-analysis aimed to investigate the adjuvant effect and safety of Shenfu injection (SFI) on the treatment of post-acute myocardial infarction heart failure (PAMIHF). Methods: Seven databases were searched to identify randomized controlled trials (RCTs) associated with SFI and PAMIHF treatment from May 1990 to May 2022. Primary outcomes included NT-proBNP and left ventricular ejection fraction (LVEF), and secondary outcomes included total effective rate, BNP, heart rate (HR), cardiac output (CO), and adverse event (AE). The risk of bias evaluation was assessed by the ROB2 tool, meta-analysis, subgroup analysis, sensitivity analysis, and publication bias were conducted by RevMan5.3 software, and the Grade of Recommendations, Assessment, Development, and Evaluations (GRADE) system was used to evaluate the quality of evidence of meta results. Results: A total of 36 studies with 3231 PAMIHF patients were included. The meta results suggested that adjuvant SFI therapy was superior to conventional medical therapy alone. It improved the total effective rate [RR = 1.33; 95% CI (1.25.1.40); p < 0.00001], increased LVEF [SMD = 0.98; 95% CI (0.71, 1.24); p < 0.00001], and decreased HR [SMD = -1.14; 95% CI (-1.28, -0.99); p < 0.00001]. In addition, adjuvant SFI therapy (9.73%, 66/678) had a rate of AE lower than that of conventional medical therapy alone (21.7%, 147/677) when regarding safety [RR = 0.45; 95% CI (0.35, 0.57); p < 0.00001]. The quality of the evidence for the outcomes was rated from "very low " to "moderate. " Conclusion: Adjuvant SFI therapy was safer to improve the total effective rate and the heart function of PAMIHF patients. However, well-designed RCTs were needed to confirm the efficacy and safety of adjuvant SFI therapy in PAMIHF treatment due to the low quality of the evidence for the outcomes caused by a small sample size and unclear risk of bias existed in included studies.

学科与关键词

关键词
acute myocardial infarctionheart failureShenfu injectionmeta-analysissystematic reviewtraditional Chinese medicine
相关
加载中…
  • Efficacy and Safety of Shenfu Injection on Acute Heart Failure: A Systematic Review and Meta-Analysis
    Tao, Lanting; Mo, Zhaofan; Li, Zunjiang; Li, Shuang; Luo, Ziqing; Li, Dongli; Wang, Dawei; Zhu, Wei*; Ding, Banghan*PHYTOMEDICINE, 2023, 110: 154641.被引 2
  • A Critical Overview of Systematic Reviews of Shenfu Injection for Heart Failure
    Huang, Jinke; Wang, Yanlu; Huang, Suihe; Qin, Xiaohui; Yan, Fang; Shen, Min; Huang, Yong*Cardiovascular Therapeutics, 2021, 2021: 8816590.被引 9
  • Efficacy and safety of Puerarin injection on acute heart failure: A systematic review and meta-analysis
    Li, Zunjiang; Fan, Ye; Huang, Chunxia; Liu, Quanle; Huang, Manhua; Chen, Baijian; Peng, Zhe; Zhu, Wei*; Ding, Banghan*Frontiers in Cardiovascular Medicine, 2022, 9: 934598.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2022-11-24
卷期
第 13 卷
页码
1027131
DOI
10.3389/fphar.2022.1027131
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
Department of Science and Technology of Guangdong Province [2021A1515012224]; clinical effect evaluation of Kuanxiong aerosol on patients with "chest tightness and pain" in emergency: an open, randomized, controlled study [HT 2020-0974(KY)]; joint project of Guangzhou City and College of Guangzhou Science and Technology Bureau [202201020296]; Special Research on Traditional Chinese Medicine Science and Technology of Traditional Chinese Medicine in Guangdong Province [YN2019MJ11]

作者

  • W

    Wu, Yanhua (第一作者)

    guangdong prov hosp · 2 · guangzhou univ chinese med

  • L

    Li, Shuang

    1 · guangzhou univ chinese med

查看全部 9 位作者收起作者
  • L

    Li, Zunjiang

    2 · guangzhou univ chinese med

  • M

    Mo, Zhaofan

    2 · guangzhou univ chinese med

  • L

    Luo, Ziqing

    guangzhou univ chinese med

  • L

    Li, Dongli

    guangdong prov hosp · 2 · guangzhou univ chinese med

  • W

    Wang, Dawei

    guangzhou univ chinese med

  • Z

    Zhu, Wei (通讯)

    guangdong prov hosp

  • D

    Ding, Banghan (通讯)

    2 · guangzhou univ chinese med · guangdong prov hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417